Vironexis

Vironexis Biotherapeutics

United States · Founded 2021 · $26.0M raised

Founded
2021
Business Model
B2B
Total Funding
$26.0M
Last Round
$26.0M SeedJul 2024
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Vironexis is a clinical-stage biotechnology company developing an AAV in vivo protein platform that delivers vectorized T-cell engagers in a single intravenous dose. Its TransJoin platform is designed to improve manufacturing complexity, administration logistics, safety, durability, scalability, and patient accessibility compared with CAR-T, bispecific antibodies, and antibody-drug conjugates. The company is building a pipeline of more than 10 product candidates with the goal of bringing durable, T-cell-mediated treatment to a broader patient population.

Summary

Vironexis is a Biotech company based in United States, founded in 2021. It has raised $26.0M in total across 1 round, most recently a $26.0M Seed round in Jul 2024. Investors include Drive Capital, Future Ventures and Ensemble VC.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundJul 2024
$26.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Vironexis on Indexed.vc
<a href="https://indexed.vc/companies/vironexis"><img src="https://indexed.vc/api/badge/company/vironexis" alt="Vironexis on Indexed.vc" width="260" height="76" /></a>